Company Description
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.
It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments.
The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products.
This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.
The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services.
The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.
Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
| Country | India |
| Founded | 1984 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 25,863 |
| CEO | Erez Israeli M.B.A. |
Contact Details
Address: 8-2-337, Road No.3 Banjara Hills Hyderabad, K7 500-034 India | |
| Phone | 91 40 49002900 |
| Website | drreddys.com |
Stock Details
| Ticker Symbol | RDY |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| CIK Code | 0001135951 |
| CUSIP Number | 256135203 |
| ISIN Number | US2561352038 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Patrick Aghanian B.A., M.B.A. | Chief Executive Officer of European Generics and Member of Management Council |
| Marc Kikuchi B.A., M.B.A. | Chief Executive Officer of North America Generics and Member of Management Council |
| Venkata Ramana Motupalli M.B.A. | Chief Executive Officer of Branded Markets - India and Emerging Countries and Member of Management Council |
| Deepak Sapra M.B.A. | Chief Executive Officer of API and Services & Member of Management Council |
| Erez Israeli M.B.A. | Chief Executive Officer and Member of the Management Council |
| Gunupati Venkateswara Prasad B.E. | Co-Chairman, MD and Member of Management Council |
| Kallam Satish Reddy B.Tech., M.S. | Chairman of the Board and Member of the Management Council |
| Parag Agarwal | Chief Financial Officer and Member of Management Council |
| Archana Bhaskar B.Sc., M.B.A. | EVice President, Head of Corporate Communications, Chief Human Resources Officer and Member of Management Council |
| Sanjay Sharma B.Tech. | Executive Vice President, Global Head of Global Manufacturing and Member of Management Council |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 26, 2024 | 6-K | Report of foreign issuer |
| Jun 26, 2024 | 6-K | Report of foreign issuer |
| Jun 24, 2024 | 6-K | Report of foreign issuer |
| Jun 21, 2024 | 6-K | Report of foreign issuer |
| Jun 20, 2024 | 6-K | Report of foreign issuer |
| Jun 20, 2024 | 6-K | Report of foreign issuer |
| Jun 18, 2024 | 6-K | Report of foreign issuer |